Karyopharm Therapeutics News Releases https://investors.karyopharm.com/ Karyopharm Therapeutics News Releases en Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-reports-updated-data-phase-2b-sadal-study-2019 -- Single-Agent Oral Selinexor Induces a 28.3% Overall Response Rate,  Including a 10.2% Complete Response Rate -- -- Amongst Patients with a Complete or Partial Response, Median Duration of Response was 9.2 Months -- NEWTON, Mass. , June 19, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. Wed, 19 Jun 2019 11:05:00 -0400 Karyopharm Therapeutics News Releases 12071 Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-reports-new-and-updated-selinexor-combination-data − Once Weekly Oral Selinexor in Combination with Kyprolis® and Low Dose Dexamethasone Demonstrates 78% ORR in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma – − Once Weekly Oral Selinexor in Combination with Darzalex® and Low Dose Dexamethasone Demonstrates 73% ORR in Patients Fri, 14 Jun 2019 07:00:00 -0400 Karyopharm Therapeutics News Releases 12061 Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-therapeutics-reports-inducement-grants-under-15 NEWTON, Mass. , June 03, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 95,500 shares of Karyopharm’s Mon, 03 Jun 2019 16:05:00 -0400 Karyopharm Therapeutics News Releases 12021 Karyopharm to Participate in Upcoming Investor Conferences https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-participate-upcoming-investor-conferences-6 NEWTON, Mass. , May 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Jefferies 2019 Global Healthcare Conference Tue, 28 May 2019 07:00:00 -0400 Karyopharm Therapeutics News Releases 12006 Karyopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual Meeting https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-announces-results-clinical-studies-investigating-0 -- Oral Presentation Highlighting Updated Data from the Phase 1b/2 STOMP Study Arm Evaluating Selinexor and Dexamethasone in Combination with Darzalex® in Patients with Relapsed or Refractory Multiple Myeloma -- -- Two Posters Highlighting Updated Data from the STOMP Arms Evaluating Selinexor and Thu, 16 May 2019 11:06:00 -0400 Karyopharm Therapeutics News Releases 11996 Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award https://investors.karyopharm.com/news-releases/news-release-details/karyopharms-founder-sharon-shacham-phd-receives-nyipla-inventor -- Dr. Shacham Recognized for Research That Led to the Development of Oral Selinexor and other SINE Compounds -- NEWTON, Mass. , May 15, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, congratulates its founder, President and Chief Wed, 15 May 2019 07:00:00 -0400 Karyopharm Therapeutics News Releases 11991 Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-reports-first-quarter-2019-financial-results-and --  FDA Extends Review Period for Selinexor New Drug Application to July 6 , 2019 -- -- Selinexor MAA Validated in Europe ; Approval Decision Expected by End of 2019 -- -- Conference Call Scheduled for Today at 8:30 a.m. ET -- NEWTON, Mass. , May 09, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Thu, 09 May 2019 07:02:00 -0400 Karyopharm Therapeutics News Releases 11971 Karyopharm to Participate in Upcoming Investor Conferences https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-participate-upcoming-investor-conferences-5 NEWTON, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Bank of America Merrill Lynch Health Care Wed, 08 May 2019 07:00:00 -0400 Karyopharm Therapeutics News Releases 11966 Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019 https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-report-first-quarter-2019-financial-results-may-9 -- Conference Call Scheduled for Thursday, May 9, 2019 at 8:30 a.m. ET -- NEWTON, Mass. , May 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2019 financial results on Thursday, May Thu, 02 May 2019 07:00:00 -0400 Karyopharm Therapeutics News Releases 11961 Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-therapeutics-reports-inducement-grants-under-14 NEWTON, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 89,500 shares of Karyopharm’s Wed, 01 May 2019 16:05:00 -0400 Karyopharm Therapeutics News Releases 11956